News

 

 

Recently Opened Clinical Trials

Konstantin Dragnev
Professor
Cancer Mechanism

Eli Lilly, Co.
A randomized, open-label Phase 2 study evaluating LY2875358 plus erlotinib and LY2875358 monotherapy in MET diagnostic positive NSCLC patients with acquired resistance to erlotinib

Astex
A study of HSP90 inhibitor AT13387 alone and in combination with crizotinib in the treatment of Non-Small Cell Lung Cancer (NSCLC)

Marc Ernstoff
Professor
Immunology and Cancer Immunotherapy

Merck and Company
A multicenter, randomized, controlled, two-arm, Phase III study to evaluate the safety and efficacy of MK-3475 compared to ipilimumab in patients with advanced melanoma

CITN (Cancer Immunotherapy Trials Network)
A phase II trial of an Indoleamine2,3, dioxygenase-1 (IDO1) inhibitor (INCB024360) plus a multipeptide melanoma vaccine in patients with advanced melanoma (MELITAC 12.1)

Kenneth R. Meehan
Professor
Immunology and Cancer Immnotherapy

Internal Funding
A prospective randomized trial examining low and intermediate doses of cyclophosphamide for hematopoietic stem cell mobilization in patients with a hematologic malignancy